European CHMP recommends approval of modified-release hydrocortisone (Efmody) for treatment of congenital adrenal hyperplasia for patients aged 12 years and older

Efmody is a new formulation of hydrocortisone, which has been developed to mimic the physiological 24-hour profile of cortisol and reduce the early morning peak of 17-hydroxyprogesterone, a steroid precursor, vs standard glucocorticoid therapy.

Source:

European Medicines Agency